Mustang Bio Files Routine 8-K, No New Material Info
Ticker: MBIO · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1680048
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance
TL;DR
**Mustang Bio's 8-K is just a standard administrative filing, nothing new to see here.**
AI Summary
Mustang Bio, Inc. filed an 8-K on January 4, 2024, reporting an "Other Event" that occurred on December 28, 2023. This filing simply confirms the company's basic information, such as its address at 377 Plantation Street, Worcester, Massachusetts, and its listing on the NASDAQ Capital Market under the ticker MBIO. For investors, this filing is routine and doesn't disclose any new material financial or operational developments, meaning it has no immediate impact on the stock's valuation.
Why It Matters
This filing is purely administrative, confirming basic company details. It does not contain any new information that would affect an investor's decision or the company's stock price.
Risk Assessment
Risk Level: low — This filing is purely informational and does not introduce any new risks or changes to the company's operations or financial standing.
Analyst Insight
Smart investors would recognize this as a routine administrative filing that contains no new material information. No immediate action is warranted based solely on this 8-K.
Key Numbers
- $0.0001 — par value per share (the par value of Mustang Bio's common stock)
Key Players & Entities
- Mustang Bio, Inc. (company) — the registrant filing the 8-K
- NASDAQ Capital Market (company) — the exchange where Mustang Bio's common stock is registered
- MBIO (company) — the trading symbol for Mustang Bio's common stock
- December 28, 2023 (date) — date of earliest event reported
- January 4, 2024 (date) — date the 8-K was filed
- 377 Plantation Street (company) — Mustang Bio's business address
- Worcester, Massachusetts 01605 (company) — Mustang Bio's business address city, state, and zip
- 781-652-4500 (dollar_amount) — Mustang Bio's business phone number
FAQ
What is the purpose of this specific 8-K filing by Mustang Bio, Inc.?
This 8-K filing by Mustang Bio, Inc. is categorized under 'Other Events' and primarily serves to confirm basic company information and its registration details, such as its listing on the NASDAQ Capital Market under the trading symbol MBIO, as of the earliest event reported on December 28, 2023.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 28, 2023.
What is Mustang Bio, Inc.'s trading symbol and on which exchange is it registered?
Mustang Bio, Inc.'s trading symbol is MBIO, and its Common Stock, par value $0.0001 per share, is registered on the NASDAQ Capital Market.
What is the business address and phone number listed for Mustang Bio, Inc. in this filing?
The business address listed for Mustang Bio, Inc. is 377 Plantation Street, Worcester, Massachusetts 01605, and its telephone number is (781) 652-4500.
Does this 8-K filing indicate that Mustang Bio, Inc. is an emerging growth company?
No, the filing indicates with a 'check mark' that Mustang Bio, Inc. is NOT an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 608 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-01-04 16:05:12
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share MBIO NASDAQ Capital Marke
Filing Documents
- tmb-20231228x8k.htm (8-K) — 31KB
- 0001558370-24-000056.txt ( ) — 144KB
- tmb-20231228.xsd (EX-101.SCH) — 3KB
- tmb-20231228_lab.xml (EX-101.LAB) — 15KB
- tmb-20231228_pre.xml (EX-101.PRE) — 10KB
- tmb-20231228x8k_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. As previously disclosed, in connection with the sale of Mustang Bio, Inc.'s (the " Company ") leasehold interest in its cell processing facility located in Worcester, Massachusetts (the " Facility ") and associated assets relating to the manufacturing and production of cell and gene therapies at the Facility (the " Transaction ") to uBrigene (Boston) Biosciences, Inc., a Delaware corporation (" uBriGene ") and an indirect, wholly owned subsidiary of UBrigene (Jiangsu) Biosciences Co., Ltd., a Chinese contract development and manufacturing organization, the Company and uBriGene previously submitted a voluntary notice with the U.S. Committee on Foreign Investment in the United States (" CFIUS ") to obtain clearance for the Transaction, although obtaining such clearance was not a condition to closing the Transaction. Following an initial 45-day review period and subsequent 45-day investigation period, on November 13, 2023, CFIUS requested the Company and uBriGene withdraw and re-file their joint voluntary notice to allow more time for review and discussion regarding the nature and extent of national security risk posed by the Transaction. Upon CFIUS's request, the Company and uBriGene submitted a request to withdraw and re-file their joint voluntary notice to CFIUS, and on November 13, 2023, CFIUS granted this request, accepted the joint voluntary notice and commenced a new 45-day review period on November 14, 2023. CFIUS's new 45-day review was completed on December 28, 2023. Because CFIUS has not yet concluded its action, the proceeding will transition to a second 45-day phase as CFIUS investigates the Transaction. CFIUS advised counsel for the Company that its investigation will be completed no later than February 12, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mustang Bio, Inc. (Registrant) Date: January 4, 2024 By: /s/ Manuel Litchman, M.D. Manuel Litchman, M.D. President, Chief Executive Officer and Interim Chief Financial Officer